title: Hyponatremia following esclicarbazepine therapy.
abstract: OBJECTIVE
  To evaluate the safety of eslicarbazepine acetate (ESL) in new onset elderly poststroke seizure patients, especially with respect to hyponatremia.
  
  
  METHODS
  In a two year, single center open labeled observational study of ESL in patients with imaging proven stroke with new onset post stroke seizure were included. ESL was titrated between 400mg and 1200 mg once daily during 1 month observation period. The titrated dose of ESL was continued during 96-week maintenance period. The patients were followed up for seizure control and side effects, including serum sodium on first examination, at the end of 1 month and then at three monthly intervals for 24 months (total eight visits).
  
  
  RESULTS
  Hyponatremia developed in four out of 32 (12.5%) patients; it was symptomatic in three and asymptomatic in one patient. No statistically significant difference between mean sodium levels at different time period, compared to baseline was found.
  
  
  CONCLUSIONS
  High incidence of hyponatremia in ESL treated post stroke patients, was found, hyponatremia symptoms since can be subtle and delayed, so monitoring of serum sodium in the patients on ESL treatment is recommended especially in elderly.
authors.affiliation: Department of Neurology, Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow, India.
authors.forename: Durgesh K
authors.initials: DK
authors.lastname: Gupta
authors.affiliation: Department of Neurology, Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow, India.
authors.forename: Sanjeev K
authors.initials: SK
authors.lastname: Bhoi
authors.affiliation: Department of Neurology, Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow, India.
authors.forename: Jayantee
authors.initials: J
authors.lastname: Kalita
authors.affiliation: Department of Neurology, Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow, India. Electronic address: drukmisra@rediffmail.com.
authors.forename: Usha K
authors.initials: UK
authors.lastname: Misra
mesh_terms: D000367:Age Factors; D000927:Anticonvulsants / Q000009:adverse effects* / Q000627:therapeutic use; D015897:Comorbidity; D003984:Dibenzazepines / Q000009:adverse effects* / Q000627:therapeutic use; D004305:Dose-Response Relationship, Drug; D004341:Drug Evaluation; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007010:Hyponatremia / Q000097:blood / Q000139:chemically induced* / Q000453:epidemiology*; D015994:Incidence; D008297:Male; D008875:Middle Aged; D012640:Seizures / Q000188:drug therapy / Q000453:epidemiology / Q000209:etiology / Q000503:physiopathology; D012964:Sodium / Q000097:blood; D020521:Stroke / Q000150:complications / Q000453:epidemiology / Q000473:pathology / Q000503:physiopathology; D061567:Voltage-Gated Sodium Channel Blockers / Q000009:adverse effects / Q000627:therapeutic use
chemical_list: D000927:Anticonvulsants; D003984:Dibenzazepines; D061567:Voltage-Gated Sodium Channel Blockers; D012964:Sodium; C416835:eslicarbazepine acetate
keywords: Antiepileptic; Esclicarbazepine; Hyponatremia; Poststroke; Seizure